BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29745326)

  • 1. A Novel Surfactant-free Lipid-based Formulation for Improving Oral Bioavailability of Loratadine Using Colloidal Silicon Dioxide as Emulsifier and Solid Carrier.
    Huang R; Tan Y; Shen L; Wang T; Quan D
    Curr Pharm Biotechnol; 2018; 19(3):217-223. PubMed ID: 29745326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state.
    Weerapol Y; Limmatvapirat S; Jansakul C; Takeuchi H; Sriamornsak P
    Eur J Pharm Biopharm; 2015 Apr; 91():25-34. PubMed ID: 25615879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of inorganic mesoporous carriers on 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol-loaded solid self-emulsifying drug delivery system: Physicochemical characterization and bioavailability in rats.
    Kim DS; Yang ES; Yong CS; Youn YS; Oh KT; Li DX; Kim JO; Jin SG; Choi HG
    Colloids Surf B Biointerfaces; 2017 Dec; 160():331-336. PubMed ID: 28957774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers.
    Noehr-Jensen L; Damkier P; Bidstrup TB; Pedersen RS; Nielsen F; Brosen K
    Eur J Clin Pharmacol; 2006 Jun; 62(6):437-45. PubMed ID: 16770647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier.
    Oh DH; Kang JH; Kim DW; Lee BJ; Kim JO; Yong CS; Choi HG
    Int J Pharm; 2011 Nov; 420(2):412-8. PubMed ID: 21944892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication of lipidic nanocarriers of loratadine for facilitated intestinal permeation using multivariate design approach.
    Verma S; Singh SK; Verma PR
    Drug Dev Ind Pharm; 2016; 42(2):288-306. PubMed ID: 26087658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of solid carriers in pharmaceutical performance of solid supersaturable SEDDS of celecoxib.
    Chavan RB; Modi SR; Bansal AK
    Int J Pharm; 2015 Nov; 495(1):374-384. PubMed ID: 26364711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing in vitro dissolution and in vivo bioavailability of fenofibrate by solid self-emulsifying matrix combined with SBA-15 mesoporous silica.
    Quan G; Wu Q; Zhang X; Zhan Z; Zhou C; Chen B; Zhang Z; Li G; Pan X; Wu C
    Colloids Surf B Biointerfaces; 2016 May; 141():476-482. PubMed ID: 26896653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
    Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery.
    Martinac A; Filipović-Grcić J; Voinovich D; Perissutti B; Franceschinis E
    Int J Pharm; 2005 Mar; 291(1-2):69-77. PubMed ID: 15707733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pre-formulation studies of the H1-antihistamine loratadine for a topical dosage form].
    Capková Z; Vitková Z; Vysokaiová V
    Ceska Slov Farm; 2005 May; 54(3):109-13. PubMed ID: 15945456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel cilostazol-loaded solid SNEDDS using a SPG membrane emulsification technique: Physicochemical characterization and in vivo evaluation.
    Mustapha O; Kim KS; Shafique S; Kim DS; Jin SG; Seo YG; Youn YS; Oh KT; Lee BJ; Park YJ; Yong CS; Kim JO; Choi HG
    Colloids Surf B Biointerfaces; 2017 Feb; 150():216-222. PubMed ID: 27918966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid self-microemulsifying drug delivery system of ritonavir.
    Deshmukh A; Kulkarni S
    Drug Dev Ind Pharm; 2014 Apr; 40(4):477-87. PubMed ID: 23465049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
    Ramasahayam B; Eedara BB; Kandadi P; Jukanti R; Bandari S
    Drug Dev Ind Pharm; 2015 May; 41(5):753-63. PubMed ID: 24641324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.
    Van Speybroeck M; Williams HD; Nguyen TH; Anby MU; Porter CJ; Augustijns P
    Mol Pharm; 2012 Sep; 9(9):2750-60. PubMed ID: 22870936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
    Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
    Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of loratadine nanocrystal tablets to improve the solubility and dissolution for enhanced oral bioavailability.
    Li J; Zhou Y; Aisha M; Wu J; Wang H; Huang F; Sun M
    J Pharm Pharmacol; 2021 Jun; 73(7):937-946. PubMed ID: 33963858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.